A Phase 2 Open Label Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 17 Mar 2019
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisolone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 31 Aug 2018 Biomarkers information updated
- 29 Mar 2018 Status changed from active, no longer recruiting to completed.
- 19 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Nov 2020.